

Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy

Michaela Yuen, ... , Kathryn N. North, Nigel F. Clarke

J Clin Invest. 2015;125(1):456-457. <https://doi.org/10.1172/JCI80057>.

Corrigendum

Original citation: *J Clin Invest.* 2014;124(11):4693–4708. doi:10.1172/JCI75199. Citation for this corrigendum: *J Clin Invest.* 2015;125(1):456–457. doi:10.1172/JCI80057. In the original version of the article, the mutation c.601_602delGA in LMOD3 was incorrectly described; the correct predicted protein change is p.D201Qfs*9. In addition, the LMOD3 mutation p.S47Qfs*13 was incorrectly indicated; the correct mutation is S47Qfs*13. These errors affected portions of Table 1, Table 2, Figure 1, and Supplemental Table 2. The corrected versions of Table 1, Table 2, and Figure 1 appear below, and Supplemental Table 2 has been updated online. The authors regret the errors.

Find the latest version:

<https://jci.me/80057/pdf>



Corrigendum

Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy

Michaela Yuen, Sarah A. Sandaradura, James J. Dowling, Alla S. Kostyukova, Natalia Moroz, Kate G. Quinlan, Vilma-Lotta Lehtokari, Gianina Ravenscroft, Emily J. Todd, Ozge Ceyhan-Birsoy, David S. Gokhin, Jérôme Maluenda, Monkol Lek, Flora Nolent, Christopher T. Pappas, Stefanie M. Novak, Adele D'Amico, Edoardo Malfatti, Brett P. Thomas, Stacey B. Gabriel, Namrata Gupta, Mark J. Daly, Biljana Ilkovski, Peter J. Houweling, Ann E. Davidson, Lindsay C. Swanson, Catherine A. Brownstein, Vandana A. Gupta, Livija Medne, Patrick Shannon, Nicole Martin, David P. Bick, Anders Flisberg, Eva Holmberg, Peter Van den Bergh, Pablo Lapunzina, Leigh B. Waddell, Darcée D. Sloboda, Enrico Bertini, David Chitayat, William R. Telfer, Annie Laquerrière, Carol C. Gregorio, Coen A.C. Ottenheijm, Carsten G. Bönnemann, Katarina Pelin, Alan H. Beggs, Yukiko K. Hayashi, Norma B. Romero, Nigel G. Laing, Ichizo Nishino, Carina Wallgren-Pettersson, Judith Melki, Velia M. Fowler, Daniel G. MacArthur, Kathryn N. North, and Nigel F. Clarke

Original citation: *J Clin Invest.* 2014;124(11):4693–4708. doi:10.1172/JCI75199.

Citation for this corrigendum: *J Clin Invest.* 2015;125(1):456–457. doi:10.1172/JCI80057.

In the original version of the article, the mutation c.601_602delGA in *LMOD3* was incorrectly described; the correct predicted protein change is p.D201Qfs*9. In addition, the *LMOD3* mutation p.S47Qfs*13 was incorrectly indicated; the correct mutation is S47Qfs*13. These

errors affected portions of Table 1, Table 2, Figure 1, and Supplemental Table 2. The corrected versions of Table 1, Table 2, and Figure 1 appear below, and Supplemental Table 2 has been updated online.

The authors regret the errors.

Table 1. *LMOD3* variants and protein expression

Patient ID	<i>LMOD3</i> genotype ^A	Protein expression ^B
1a	hom c.138dupC, p.S47Qfs*13	p.S47Qfs*13 (6.6 kDa), no expression
1b	hom c.138dupC, p.S47Qfs*13	p.S47Qfs*13 (6.6 kDa), N/D
2	hom c.138dupC, p.S47Qfs*13	p.S47Qfs*13 (6.6 kDa), N/D
3	hom c.154delA, p.M52*	3a and 3b - p.M52* (5.7 kDa), N/D
4	hom c.231G>A, p.W77*	p.W77* (8.7 kDa), no expression
5	het c.300_304delGACTC, p.T101Rfs*4 het c.601_602delGA, p.D201Qfs*9	p.T101Rfs*4 (12 kDa), no expression p.D201Qfs*9 (24 kDa), no expression
6	hom c.349C>T, p.Q117*	p.Q117* (13.6 kDa), inconclusive
7	het c.349C>T, p.Q117* het c.1218delA, p.K406Nfs*11	p.Q117* (13.6 kDa), inconclusive p.K406Nfs*11 (48.2 kDa), inconclusive
8	het c.723_733del, p.D242Efs*4 het c.976G>C, p.G326R	p.G326R p.D242Efs*4 (28.3 kDa), N/D
9	hom c.860delT, p.F287Sfs*3	p.F287Sfs*3 (33 kDa), no expression
10	het c.976G>C, p.G326R het c.1372C>T, p.Q458*	p.Q458* (52.9 kDa), N/D p.G326R
11a	hom c.1069G>T, p.E357*	p.E357* (41.1 kDa), N/D
11b	hom c.1069G>T, p.E357*	p.E357* (41.1 kDa), N/D
12a ^C	hom c.1099_1100delAA, p.N367Qfs*11	p.N367Qfs*11 (43 kDa), no expression
12b	hom c.1099_1100delAA, p.N367Qfs*11	p.N367Qfs*11 (43 kDa), N/D
12c	hom c.1099_1100delAA, p.N367Qfs*11	p.N367Qfs*11 (43 kDa), no expression
13a	hom c.1099_1100delAA, p.N367Qfs*11	p.N367Qfs*11 (43 kDa), N/D
13b	hom c.1099_1100delAA, p.N367Qfs*11	p.N367Qfs*11 (43 kDa), N/D
14a	het c.1100_1102delACA, p.N367del het c.1201C>T, p.R401*	p.R401* (48 kDa), expressed p.N367del (64.8 kDa), expressed
14b	het c.1100_1102delACA, p.N367del het c.1201C>T, p.R401*	p.N367del, N/D p.R401*, N/D

^ANumbering of the nucleotide and protein changes is relative to NM_198271.3 (gene) and NP_938012 (protein). ^BFull-length *LMOD3* protein is 560–amino acids long and has a predicted molecular weight of 64.9 kDa. Molecular weight predictions were performed using ExpASY (http://web.expasy.org/compute_pi/). The presence or absence of protein expression was assessed by Western blot analysis. ^CCorresponds to BOS-1120. Hom, homozygous; het, heterozygous; N/D, not determined (no muscle was available for analysis); inconclusive, biopsy contained only small amounts of muscle tissue, and the presence or absence of mutant *LMOD3* expression could not be determined conclusively.

Table 2. Clinical features of *LMOD3*-NM

Patient ID	Genotype	Ethnicity	Sex	Clinical subtype ^a	Clinical features
1a	p.S47Qfs*13	Algerian	F	SC	Deceased (neonatal period) ^b . Polyhydramnios, preterm delivery (30/40), arthrogryposis, fractures (bilateral femoral).
1b	p.S47Qfs*13	Algerian	F	SC	Deceased (neonatal period). Preterm delivery (36/40).
2	p.S47Qfs*13	Belgian	M	SC	Deceased (10 months). Decreased fetal movements, breech presentation, arthrogryposis, ophthalmoplegia.
3a	p.M52*	Portuguese	F	SC	Deceased (neonatal period). Polyhydramnios, decreased fetal movements, contractures.
3b	p.M52*	Portuguese	F	SC	Alive at 1 month, lost to follow-up. Polyhydramnios, contractures.
4	p.W77*	Japanese	M	SC	Alive at 4 months, lost to follow-up.
5	p.T101Rfs*4 / p.D201Qfs*9	Japanese	F	SC	Alive at 2 months, lost to follow-up. Polyhydramnios, decreased fetal movements, subdural hematoma.
6	p.Q117*	Japanese	F	SC	Alive at 10 months, lost to follow-up. Polyhydramnios, decreased fetal movements, fetal edema, preterm delivery (32/40), microcephaly, contractures.
7	p.Q117* / p.K406Nfs*11	Japanese	F	SC	Alive at 1 year 7 months, lost to follow-up. Polyhydramnios, decreased fetal movements, ophthalmoplegia.
8	p.D242Efs*4 / p.G326R	South American	F	SC	Deceased (neonatal period).
9	p.F287Sfs*3	Italian	F	SC	Deceased (4 months). Polyhydramnios, decreased fetal movements, preterm delivery (34/40), ophthalmoplegia, contractures.
10	p.G326R / p.Q458*	Ecuadorian	M	SC	Deceased (6 weeks). Polyhydramnios, decreased fetal movements, preterm delivery (35/40), breech presentation, ophthalmoplegia, arthrogryposis, fractures (bilateral humeral).
11a	p.E357*	Swedish	M	SC	Deceased (5 months). Polyhydramnios, arthrogryposis.
11b	p.E357*	Swedish	M	SC	Deceased (neonatal period).
12a ^c	p.N367Qfs*11	Afghani	M	SC	Deceased (2 months). Absent fetal movements, preterm delivery (31/40), breech presentation, arthrogryposis.
12b	p.N367Qfs*11	Afghani	M	SC	Deceased (neonatal period). Preterm delivery (33/40), arthrogryposis.
12c	p.N367Qfs*11	Afghani			Affected fetus.
13a	p.N367Qfs*11	Pakistani	F	SC	Deceased (3 months). Polyhydramnios, breech presentation, ophthalmoplegia, kyphosis.
13b	p.N367Qfs*11	Pakistani	F	SC	Deceased (neonatal period). Polyhydramnios, decreased fetal movements.
14a	p.N367del / p.R401*	Australian	F	TC	Alive (10 years). Polyhydramnios, decreased fetal movements, bulbar weakness, ophthalmoplegia, percutaneous endoscopic gastrostomy, nocturnal noninvasive ventilation. Walks independently. Normal cardiac assessment and echocardiogram.
14b	p.N367del / p.R401*	Australian	F	TC	Alive (4 years). Polyhydramnios, bulbar weakness, percutaneous endoscopic gastrostomy, nocturnal noninvasive ventilation. Walks with truncal support. Normal cardiac assessment and echocardiogram.

^aClassification of clinical subtype of NM relates to the European Neuromuscular Centre classification of NM (1). ^bNeonatal period indicates less than 28 days of age. ^cCorresponds to BOS-1120. TC, typical congenital NM; SC, severe congenital NM; F, female; M, male; 30/40, gestational age of 30 weeks.

Figure 1

